

Chapter 36

Eosinophils in Cutaneous Diseases

Kristin M. Leiferman & Margot S. Peters

REFERENCES

1. Leiferman KM: A current perspective on the role of eosinophils in dermatologic diseases. *J Am Acad Dermatol* **24**(6 Pt 2):1101-1112, 1991
2. Gleich GJ: Mechanisms of eosinophil-associated inflammation. *J Allergy Clin Immunol* **105**(4):651-663, 2000
3. Rothenberg ME, Hogan SP: The eosinophil. *Annu Rev Immunol* **24**:147-174, 2006
4. Simon D, Wardlaw A, Rothenberg ME: Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. *J Allergy Clin Immunol* **126**(1):3-13, 2010
5. Zuo L, Rothenberg ME: Gastrointestinal eosinophilia. *Immunol Allergy Clin North Am* **27**(3):443-455, 2007 [PMID: 2034402]
6. Wechsler ME: Pulmonary eosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):477-492, 2007
7. Klion AD, Nutman TB: The role of eosinophils in host defense against helminth parasites. *J Allergy Clin Immunol* **113**(1):30-37, 2004
8. Kephart GM, Andrade ZA, Gleich GJ: Localization of eosinophil major basic protein onto eggs of *Schistosoma mansoni* in human pathologic tissue. *Am J Pathol* **133**(2):389-396, 1988
9. Emmerson RW, Wilson-Jones E: Eosinophilic spongiosis in pemphigus. A report of an unusual histological change in pemphigus. *Arch Dermatol* **97**(3):252-257, 1968
10. Crotty C, Pittelkow M, Muller SA: Eosinophilic spongiosis: A clinicopathologic review of seventy-one cases. *J Am Acad Dermatol* **8**(3):337-343, 1983
11. Winkelmann RK, Frigas E: Eosinophilic panniculitis: A clinicopathologic study. *J Cutan Pathol* **13**(1):1-12, 1986
12. Adame J, Cohen PR: Eosinophilic panniculitis: Diagnostic considerations and evaluation. *J Am Acad Dermatol* **34**(2 Pt 1):229-234, 1996
13. Trocme SD et al: Extracellular deposition of eosinophil major basic protein in orbital histiocytosis X. *Ophthalmology* **98**(3):353-356, 1991
14. Quaedvlieg PJ et al: Histopathological characteristics of metastasizing squamous cell carcinoma of the skin and lips. *Histopathology* **49**(3):256-264, 2006
15. Butterfield JH et al: Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin's disease. *Blood* **68**(6):1250-1256, 1986
16. Weaver J, Bergfeld WF: Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions. *Am J Dermatopathol* **32**(1):31-34, 2010
17. Marra DE, McKee PH, Nghiem P: Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. *J Am Acad Dermatol* **51**(4):543-546, 2004
18. Leiferman KM, Peters MS, Gleich GJ: The eosinophil and cutaneous edema. *J Am Acad Dermatol* **15**(3):513-517, 1986
19. Romero LS, Kantor GR: Eosinophils are not a clue to the pathogenesis of granuloma annulare. *Am J Dermatopathol* **20**(1):29-34, 1998
20. Hardy WR, Anderson RE: The hypereosinophilic syndromes. *Ann Intern Med* **68**:1220-1229, 1968
21. Chusid MJ et al: The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. *Medicine (Baltimore)* **54**(1):1-27, 1975
22. Simon HU et al: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. *N Engl J Med* **341**(15):1112-1120, 1999
23. Roufosse F, Cogan E, Goldman M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. *Allergy* **59**(7):673-689, 2004
24. Gleich GJ et al: Treatment of hypereosinophilic syndrome with imatinib mesilate. *Lancet* **359**(9317):1577-1578, 2002
25. Cools J et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* **348**(13):1201-1214, 2003

26. Gotlib J et al: The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. *Blood* **103**(8):2879-2791, 2004
27. Bain BJ, Fletcher SH: Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. *Immunol Allergy Clin North Am* **27**(3):377-388, 2007
28. Gleich GJ, Leiferman KM: The hypereosinophilic syndromes: Still more heterogeneity. *Curr Opin Immunol* **17**(6):679-684, 2005
29. Klion AD et al: Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. *J Allergy Clin Immunol* **117**(6):1292-1302, 2006
30. Simon HU et al: Refining the definition of hypereosinophilic syndrome. *J Allergy Clin Immunol* **126**(1):45-49, 2010
31. Rothenberg ME: Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol* **113**(1):11-28, quiz 29, 2004
32. Noel RJ, Putnam PE, Rothenberg ME: Eosinophilic esophagitis. *N Engl J Med* **351**(9):940-941, 2004
33. Bochner BS, Gleich GJ: What targeting eosinophils has taught us about their role in diseases. *J Allergy Clin Immunol* **126**(1):16-25, 2010
34. Roufousse F, Cogan E, Goldman M: Lymphocytic variant hypereosinophilic syndromes. *Immunol Allergy Clin N Am* **27**:389-413, 2007
35. Pardanani A et al: FIP1L1-PDGFR fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood* **104**(10):3038-3045, 2004
36. Tefferi A, Pardanani A, Li CY: Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? *Blood* **102**(8):3073-3074, author reply 3074, 2003
37. Pardanani A et al: CHIC2 deletion, a surrogate for FIP1L1-PDGFR fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood* **102**(9):3093-3096, 2003
38. Yamada Y et al: The FIP1L1-PDGFR fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. *Blood* **107**(10):4071-4079, 2006
39. Yamada Y, Cancelas JA: FIP1L1/PDGFR alpha-associated systemic mastocytosis. *Int Arch Allergy Immunol* **152**(Suppl. 1):101-105, 2010
40. Vardiman JW et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* **114**(5):937-951, 2009
41. Tefferi A, Thiele J, Vardiman JW: The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos. *Cancer* **115**(17):3842-3847, 2009
42. Gleich GJ et al: Episodic angioedema associated with eosinophilia. *N Engl J Med* **310**(25):1621-1626, 1984
43. Butterfield JH, Leiferman KM, Gleich GJ: Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): A novel eosinophilic disorder. *Clin Exp Allergy* **23**(7):571-580, 1993
44. Roufousse F, Weller PF: Practical approach to the patient with hypereosinophilia. *J Allergy Clin Immunol* **126**(1):39-44, 2010
45. Ogbogu PU et al: Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. *J Allergy Clin Immunol* **124**(6):1319-1325, e3, 2009 [PMID: 2829669]
46. Sheikh J, Weller PF: Clinical overview of hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):333-355, 2007
47. van den Hoogenband HM: Skin lesions as the first manifestation of the hypereosinophilic syndrome. *Clin Exp Dermatol* **7**(3):267-271, 1982
48. Leiferman KM, Gleich GJ, Peters MS: Dermatologic manifestations of the hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):415-441, 2007
49. Roufousse F, Simonart T, Cogan E: Skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome. *Br J Dermatol* **144**(3):639, 2001
50. Offidani A et al: Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome? *Br J Dermatol* **143**(3):675-677, 2000
51. Barna M, Kemeny L, Dobozy A: Skin lesions as the only manifestation of the hypereosinophilic syndrome. *Br J Dermatol* **136**(4):646-647, 1997
52. Kazmierowski JA et al: Dermatologic manifestations of the hypereosinophilic syndrome. *Arch Dermatol* **114**(4):531-535, 1978
53. Miljkovic J, Bartenjev I: Hypereosinophilic dermatitis-like erythema annulare centrifugum in a patient with chronic lymphocytic leukaemia. *J Eur Acad Dermatol Venereol* **19**(2):228-231, 2005

54. Calux MJ et al: [Hypereosinophilic syndrome. Cutaneous picture of "erythema annulare centrifugum"—Comparison with ultrastructural study]. [Article in Portuguese.] *Med Cutan Ibero Lat Am* **16**(4):299-304, 1988
55. Shelley WB, Shelley ED: Erythema annulare centrifugum as the presenting sign of the hypereosinophilic syndrome: Observations on therapy. *Cutis* **35**(1):53-55, 1985
56. Hofmann SC et al: Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib. *J Am Acad Dermatol* **56**(Suppl. 5):S68-S72, 2007
57. McPherson T et al: Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. *Br J Dermatol* **155**(4):824-826, 2006
58. Jang KA et al: Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud's phenomenon complicated by digital gangrene. *Br J Dermatol* **143**(3):641-644, 2000
59. Kim SH et al: Hypereosinophilia presenting as eosinophilic vasculitis and multiple peripheral artery occlusions without organ involvement. *J Korean Med Sci* **20**(4):677-679, 2005
60. Ito K et al: Hypereosinophilic syndrome with various skin lesions and juvenile temporal arteritis. *Clin Exp Dermatol* **34**(5):e192-e195, 2009
61. Hayashi M et al: Case of hypereosinophilic syndrome with cutaneous necrotizing vasculitis. *J Dermatol* **35**(4):229-233, 2008
62. Tsuji Y et al: Wells' syndrome as a manifestation of hypereosinophilic syndrome. *Br J Dermatol* **147**(4):811-812, 2002
63. Bogenrieder T et al: Wells' syndrome associated with idiopathic hypereosinophilic syndrome. *Br J Dermatol* **137**(6):978-982, 1997
64. Leiferman KM, Gleich GJ: Hypereosinophilic syndrome: Case presentation and update. *J Allergy Clin Immunol* **113**(1):50-58, 2004
65. Vandenberghe P et al: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. *Leukemia* **18**(4):734-742, 2004
66. Leiferman KM et al: Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. *JAMA* **247**(7):1018-1020, 1982
67. Ogbogu PU, Rosing DR, Horne MK III. Cardiovascular manifestations of hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):457-475, 2007 [PMID: 2048688]
68. Fuzellier JF, Chapoutot L, Torossian PF: Mitral valve repair in idiopathic hypereosinophilic syndrome. *J Heart Valve Dis* **13**(3):529-531, 2004
69. Blauwet LA et al: Atypical presentation of eosinophilic endomyocardial disease. *Mayo Clin Proc* **80**(8):1078-1084, 2005
70. Klion A: Hypereosinophilic syndrome: Current approach to diagnosis and treatment. *Annu Rev Med* **60**:293-306, 2009
71. Gleich GJ, Leiferman KM: The hypereosinophilic syndromes: Current concepts and treatments. *Br J Haematol* **145**(3):271-285, 2009
72. Tefferi A, Gotlib J, Pardanani A: Hypereosinophilic syndrome and clonal eosinophilia: Point-of-care diagnostic algorithm and treatment update. *Mayo Clin Proc* **85**(2):158-164, 2010 [PMID: 2813824]
73. Plager DA et al: Eosinophil ribonucleases and their cutaneous lesion-forming activity. *J Immunol* **183**(6):4013-4020, 2009 [PMID: 2852253]
74. Nutman TB: Evaluation and differential diagnosis of marked, persistent eosinophilia. *Immunol Allergy Clin North Am* **27**(3):529-549, 2007. [PMID: 2099264]
75. Lee JS et al: Prolonged urticaria with purpura: The spectrum of clinical and histopathologic features in a prospective series of 22 patients exhibiting the clinical features of urticarial vasculitis. *J Am Acad Dermatol* **56**(6):994-1005, 2007
76. Amano H, Nagai Y, Ishikawa O: Persistent urticaria characterized by recurrent lasting urticarial erythema with histological features of prominent perivascular eosinophilic infiltration. *Clin Exp Dermatol* **34**(5):e14-e17, 2009
77. Klion AD: Approach to the therapy of hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):551-560, 2007
78. Simon HU, Cools J: Novel approaches to therapy of hypereosinophilic syndromes. *Immunol Allergy Clin North Am* **27**(3):519-527, 2007
79. Pitini V et al: Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. *Blood* **102**(9):3456-3457, author reply 3457, 2003
80. Sato Y et al: Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: A sensitive non-invasive marker of cardiac disorder. *Intern Med* **39**(4):350, 2000
81. Burgess MR, Sawyers CL: Treating imatinib-resistant leukemia: The next generation targeted therapies. *Scientific World J* **6**:918-930, 2006

82. O'Hare T, Corbin AS, Druker BJ: Targeted CML therapy: Controlling drug resistance, seeking cure. *Curr Opin Genet Dev* **16**(1):92-99, 2006
83. Simon D et al: Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. *J Allergy Clin Immunol* **121**:1054-1056, 2008
84. Scowden EB, Schaffner W, Stone WJ: Overwhelming strongyloidiasis: An unappreciated opportunistic infection. *Medicine (Baltimore)* **57**(6):527-544, 1978
85. Rotoli B et al: Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. *Leuk Lymphoma* **45**(12):2503-2507, 2004
86. Klion AD et al: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. *Blood* **103**(2):473-478, 2004
87. Butterfield JH: Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. *Acta Haematol* **114**(1):26-40, 2005
88. Butterfield JH: Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. *Immunol Allergy Clin North Am* **27**(3):493-518, 2007
89. Cervetti G et al: Imatinib therapy in Hypereosinophilic Syndrome: A case of molecular remission. *Leuk Res* **29**(9):1097-1098, 2005
90. Tefferi A: Modern diagnosis and treatment of primary eosinophilia. *Acta Haematol* **114**(1):52-60, 2005
91. Taverna JA et al: Infliximab as a therapy for idiopathic hypereosinophilic syndrome. *Arch Dermatol* **143**(9):1110-1112, 2007
92. Sefcick A et al: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. *Br J Haematol* **124**(4):558-559, 2004
93. Wagner LA et al: Treatment of FIP1L1/PDGFR α -negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. *J Allergy Clin Immunol* **123**(6):1407-1408, 2009
94. Pitini V et al: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: A case report. *Br J Haematol* **127**(5):477, 2004
95. Halaburda K et al: Allogeneic bone marrow transplantation for hypereosinophilic syndrome: Long-term follow-up with eradication of FIP1L1-PDGFR α fusion transcript. *Bone Marrow Transplant* **38**(4):319-320, 2006
96. Ueno NT et al: Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. *Br J Haematol* **119**(1):131-134, 2002
97. Walsh GM: Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. *Curr Opin Mol Ther* **11**(3):329-336, 2009
98. Klion AD et al: Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH36 in the treatment of patients with hypereosinophilic syndrome. *Blood* **103**(8):2939-2941, 2004
99. Rothenberg ME et al: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. *N Engl J Med* **358**(12):1215-1228, 2008
100. Plotz SG et al: Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. *N Engl J Med* **349**(24):2334-2339, 2003
101. Boucher RM, Gilbert-McClain L, Chowdhury B: Hypereosinophilic syndrome and mepolizumab. *N Engl J Med* **358**(26):2838-2839, author reply 2839-2840, 2008
102. Wells GC: Recurrent granulomatous dermatitis with eosinophilia. *Trans St Johns Hosp Dermatol Soc* **57**:46-56, 1971
103. Wells GC, Smith NP: Eosinophilic cellulitis. *Br J Dermatol* **100**(1):101-109, 1979
104. Spigel GT, Winkelmann RK: Wells' syndrome. Recurrent granulomatous dermatitis with eosinophilia. *Arch Dermatol* **115**(5):611-613, 1979
105. Leiferman KM, Peters MS: Reflections on eosinophils and flame figures: Where there's smoke there's not necessarily Wells syndrome. *Arch Dermatol* **142**(9):1215-1218, 2006
106. Van den Hoogenband HM: Eosinophilic cellulitis as a result of onchocerciasis. *Clin Exp Dermatol* **8**:405-408, 1983
107. Fisher GB, Greer KE, Cooper PH: Eosinophilic cellulitis (Wells' syndrome). *Int J Dermatol* **24**(2):101-107, 1985
108. Gilliam AE et al: Bullous "cellulitis" with eosinophilia: case report and review of Wells' syndrome in childhood. *Pediatrics* **116**(1):e149-e155, 2005
109. Ling TC et al: Two cases of bullous eosinophilic cellulitis. *Br J Dermatol* **146**(1):160-161, 2002
110. Schuttelaar ML, Jonkman MF: Bullous eosinophilic cellulitis (Wells' syndrome) associated with Churg-Strauss syndrome. *J Eur Acad Dermatol Venereol* **17**(1):91-93, 2003

111. Schorr WF et al: Eosinophilic cellulitis (Wells' syndrome): histologic and clinical features in arthropod bite reactions. *J Am Acad Dermatol* 11(6):1043-1049, 1984
112. Aberer W, Konrad K, Wolff K: Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. *J Am Acad Dermatol* 18(1 Pt 1):105-114, 1988
113. Peters MS, Schroeter AL, Gleich GJ: Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. *Br J Dermatol* 109(2):141-148, 1983
114. Brehmer-Andersson E et al: The histopathogenesis of the flame figure in Wells' syndrome based on five cases. *Acta Derm Venereol* 66(3):213-219, 1986
115. Caputo R et al: Wells syndrome in adults and children: A report of 19 cases. *Arch Dermatol* 142(9):1157-1161, 2006
116. Davis MD et al: Familial eosinophilic cellulitis, dysmorphic habitus, and mental retardation. *J Am Acad Dermatol* 38(6 Pt 1):919-928, 1998
117. Melski JW: Wells' syndrome, insect bites, and eosinophils. *Dermatol Clin* 8(2):287-293, 1990
118. Lin HL et al: Eosinophilic cellulitis after honeybee sting. *J Formos Med Assoc* 108(12):964-966, 2009
119. Gambichler T et al: Impetiginized Wells' syndrome in a patient with chronic lymphocytic leukaemia. *Clin Exp Dermatol* 34(7):e274-e275, 2009
120. Utikal J et al: Bullous eosinophilic cellulitis associated with ulcerative colitis: Effective treatment with sulfasalazine and glucocorticoids. *Br J Dermatol* 156(4):764-766, 2007
121. Hirsch K et al: Eosinophilic cellulitis (Wells' syndrome) associated with colon carcinoma. *J Dtsch Dermatol Ges* 3(7):530-531, 2005
122. Farrar CW, Guerin DM, Wilson NJ: Eosinophilic cellulitis associated with squamous cell carcinoma of the bronchus. *Br J Dermatol* 145(4):678-679, 2001
123. Hunt SJ, Santa Cruz DJ: Eosinophilic cellulitis: Histologic features in a cutaneous mastocytoma. *Dermatologica* 182(2):132-134, 1991
124. Koh KJ et al: Wells' syndrome following thiomersal-containing vaccinations. *Australas J Dermatol* 44(3):199-202, 2003
125. Calvert J et al: Relapse of Wells' syndrome in a child after tetanus-diphtheria immunization. *J Am Acad Dermatol* 54(Suppl. 5):S232-S233, 2006
126. Moreno M et al: Wells' syndrome related to tetanus vaccine. *Int J Dermatol* 36(7):524-525, 1997
127. Fujimoto N et al: Wells syndrome associated with Churg-Strauss syndrome. *Clin Exp Dermatol* 36(1):46-48, 2011
128. French LE et al: Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: Increased production of interleukin 5 and inhibition by interferon alfa. *J Am Acad Dermatol* 49(6):1170-1174, 2003
129. Nguyen NQ, Ma L: Eosinophilic cellulitis and dermographism. *Dermatol Online J* 11(4):7, 2005
130. Hamamoto Y et al: Eosinophilic cellulitis associated with molluscum contagiosum. *Br J Dermatol* 151(6):1279-1281, 2004
131. Ludwig RJ et al: Herpes simplex virus type 2-associated eosinophilic cellulitis (Wells' syndrome). *J Am Acad Dermatol* 48(Suppl. 5):S60-S61, 2003
132. Jones-Caballero M et al: Wells' syndrome and human immunodeficiency virus infection. *Br J Dermatol* 143(3):672-674, 2000
133. Beer TW et al: Flame figures in bullous pemphigoid. *Dermatology* 188(4):310-312, 1994
134. Rossini MS et al: Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. *J Eur Acad Dermatol Venereol* 18(5):538-542, 2004
135. Winfield H et al: Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. *Arch Dermatol* 142(2):218-220, 2006
136. Perrin C et al: Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. *Am J Dermatopathol* 23(4):295-298, 2001
137. Moossavi M, Mehregan DR: Wells' syndrome: A clinical and histopathologic review of seven cases. *Int J Dermatol* 42(1):62-67, 2003
138. Espana A et al: Wells' syndrome (eosinophilic cellulitis): Correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin-5. *Br J Dermatol* 140(1):127-130, 1999
139. Katoulis AC et al: Idiopathic bullous eosinophilic cellulitis (Wells' syndrome). *Clin Exp Dermatol* 34(7):e375-e376, 2009
140. Wells GC, Whimster IW: Subcutaneous angiolymphoid hyperplasia with eosinophilia. *Br J Dermatol* 81(1):1-14, 1969
141. Wilson-Jones E, Marks R: Papular angioplasia. Vascular papules of the face and scalp simulating malignant vascular tumors. *Arch Dermatol* 102(4):422-427, 1970

142. Jones EW, Bleehen SS: Inflammatory angioma-tous nodules with abnormal blood vessels occurring about the ears and scalp (pseudo or atypical pyogenic granuloma). *Br J Dermatol* **81**(11):804-816, 1969
143. Rosai J: Angiolymphoid hyperplasia with eosinophilia of the skin. Its nosological position in the spectrum of histiocytoid hemangioma. *Am J Dermatopathol* **4**(2):175-84, 1982
144. Requena L, Sanguenza OP: Cutaneous vascular proliferation. Part II. Hyperplasias and benign neoplasms. *J Am Acad Dermatol* **37**(6):887-919, quiz 920-922, 1997
145. Zarrin-Khameh N, Spoden JE, Tran RM: Angiolymphoid hyperplasia with eosinophilia associated with pregnancy: A case report and review of the literature. *Arch Pathol Lab Med* **129**(9):1168-1171, 2005
146. Gonzalez-Cuyar LF et al: Angiolymphoid hyperplasia with eosinophilia developing in a patient with history of peripheral T-cell lymphoma: evidence for multicentric T-cell lymphoproliferative process. *Diagn Pathol* **3**:22, 2008 [PMID: 2427016]
147. Chen JF et al: Angiolymphoid hyperplasia with eosinophilia affecting the scrotum: A rare case report with molecular evidence of T-cell clonality. *J Dermatol* **37**(4):355-359, 2010
148. Effat KG: Angiolymphoid hyperplasia with eosinophilia of the auricle: Progression of histopathological changes. *J Laryngol Otol* **120**(5):411-413, 2006
149. Suzuki H et al: A case of angiolymphoid hyperplasia with eosinophilia (ALHE) of the upper lip. *J Dermatol* **32**(12):991-995, 2005
150. Helander SD et al: Kimura's disease and angiolymphoid hyperplasia with eosinophilia: New observations from immunohistochemical studies of lymphocyte markers, endothelial antigens, and granulocyte proteins. *J Cutan Pathol* **22**(4):319-326, 1995
151. Olsen TG, Helwig EB: Angiolymphoid hyperplasia with eosinophilia. A clinicopathologic study of 116 patients. *J Am Acad Dermatol* **12**(5 Pt 1):781-796, 1985
152. Cheney ML et al: Angiolymphoid hyperplasia with eosinophilia (histiocytoid hemangioma): Evaluation of treatment options. *Ann Otol Rhinol Laryngol* **102**(4 Pt 1):303-308, 1993
153. Miller CJ, Ioffreda MD, Ammirati CT: Mohs micrographic surgery for angiolymphoid hyperplasia with eosinophilia. *Dermatol Surg* **30**(8):1169-1173, 2004
154. Rampini P et al: Angiolymphoid hyperplasia with eosinophilia: Successful treatment with interferon alpha 2b. *Dermatology* **202**(4):343, 2001
155. Cooper SM, Dawber RP, Millard P: Angiolymphoid hyperplasia with eosinophilia treated by cryosurgery. *J Eur Acad Dermatol Venereol* **15**(5):489-490, 2001
156. Angel CA et al: Angiolymphoid hyperplasia successfully treated with an ultralong pulsed dye laser. *Dermatol Surg* **31**(6):713-716, 2005
157. Mashiko M et al: A case of angiolymphoid hyperplasia with eosinophilia successfully treated with tacrolimus ointment. *Br J Dermatol* **154**(4):803-804, 2006
158. Chen H et al: Kimura disease: A clinicopathologic study of 21 cases. *Am J Surg Pathol* **28**(4):505-513, 2004
159. Kimura T, Yoshimura S, Ishikawa E: Unusual granulation combined with hyperplastic changes in lymphatic tissue. *Trans Soc Pathol Jpn* **13**:179-180, 1948
160. Kung IT, Gibson JB, Bannatyne PM: Kimura's disease: A clinico-pathological study of 21 cases and its distinction from angiolymphoid hyperplasia with eosinophilia. *Pathology* **16**(1):39-44, 1984
161. Li TJ et al: Kimura's disease: A clinicopathologic study of 54 Chinese patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **82**(5):549-555, 1996
162. Wang TF et al: Kimura's disease with generalized lymphadenopathy demonstrated by positron emission tomography scan. *Intern Med* **45**(12):775-778, 2006
163. Yamada A et al: Membranous glomerulonephritis associated with eosinophilic lymphfolliculosis of the skin (Kimura's disease): Report of a case and review of the literature. *Clin Nephrol* **18**(4):211-215, 1982
164. Rajpoot DK, Pahl M, Clark J: Nephrotic syndrome associated with Kimura disease. *Pediatr Nephrol* **14**(6):486-488, 2000
165. Wang DY et al: Kimura disease: A case report and review of the Chinese literature. *Nephron Clin Pract* **111**(1):c55-c61, 2009
166. Chong WS, Thomas A, Goh CL: Kimura's disease and angiolymphoid hyperplasia with eosinophilia: Two disease entities in the same patient: Case report and review of the literature. *Int J Dermatol* **45**(2):139-145, 2006
167. Yuen HW et al: Kimura's disease: A diagnostic and therapeutic challenge. *Singapore Med J* **46**(4):179-183, 2005

168. Takeishi M et al: Kimura disease: Diagnostic imaging findings and surgical treatment. *J Craniofac Surg* **18**(5):1062-1067, 2007
169. Wang YS et al: Treatment of Kimura's disease with cyclosporine. *J Dermatolog Treat* **16**(4):242-244, 2005
170. Abuel-Haija M, Hurford MT: Kimura disease. *Arch Pathol Lab Med* **131**(4):650-651, 2007
171. Sun QF et al: Kimura disease: Review of the literature. *Intern Med J* **38**(8):668-672, 2008
172. Ofuji S et al: Eosinophilic pustular folliculitis. *Acta Derm Venereol* **50**(3):195-203, 1970
173. Lucky AW et al: Eosinophilic pustular folliculitis in infancy. *Pediatr Dermatol* **1**(3):202-206, 1984
174. Soeprono FF, Schinella RA: Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome. Report of three cases. *J Am Acad Dermatol* **14**(6):1020-1022, 1986
175. Ziemer M, Boer A: Eosinophilic pustular folliculitis in infancy: Not a distinctive inflammatory disease of the skin. *Am J Dermatopathol* **27**(5):443-455, 2005
176. Nervi SJ, Schwartz RA, Dmochowski M: Eosinophilic pustular folliculitis: A 40 year retrospect. *J Am Acad Dermatol* **55**(2):285-289, 2006
177. Takematsu H et al: Eosinophilic pustular folliculitis. Report of two cases with a review of the Japanese literature. *Arch Dermatol* **121**(7):917-920, 1985
178. Rosenthal D et al: Human immunodeficiency virus-associated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. *Arch Dermatol* **127**(2):206-209, 1991
179. Rajendran PM et al: Eosinophilic folliculitis: Before and after the introduction of antiretroviral therapy. *Arch Dermatol* **141**(10):1227-1231, 2005
180. Kimoto M, Ishihara S, Konohana A: Eosinophilic pustular folliculitis with polycythemia vera. *Dermatology* **210**(3):239-240, 2005
181. Patrizi A et al: Eosinophilic pustular folliculitis (Ofuji's disease) and non-Hodgkin lymphoma. *Acta Derm Venereol* **72**(2):146-147, 1992
182. Jang KA et al: Eosinophilic pustular folliculitis (Ofuji's disease) in myelodysplastic syndrome. *J Dermatol* **25**(11):742-746, 1998
183. Lambert J et al: Eosinophilic pustular folliculitis and B-cell chronic lymphatic leukaemia. *Dermatology* **189**(Suppl. 2):58-59, 1994
184. Keida T, Hayashi N, Kawashima M: Eosinophilic pustular folliculitis following autologous peripheral blood stem-cell transplantation. *J Dermatol* **31**(1):21-26, 2004
185. Goiriz R et al: Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: Case report and review. *J Cutan Pathol* **34**(Suppl. 1):33-36, 2007
186. Fraser SJ et al: Eosinophilic folliculitis: An important differential diagnosis after allogeneic bone-marrow transplant. *Clin Exp Dermatol* **34**(3):369-371, 2009
187. Ogawa E et al: Eosinophilic pustular folliculitis occurring after bone marrow transplantation in a child with aplastic anaemia. *Acta Derm Venereol* **89**(2):200-201, 2009
188. Opie KM et al: Two cases of eosinophilic pustular folliculitis associated with parasitic infestations. *Australas J Dermatol* **44**(3):217-219, 2003
189. Gesierich A et al: Eosinophilic folliculitis in a Caucasian patient: Association with toxocarasis? *J Eur Acad Dermatol Venereol* **20**(10):1317-1321, 2006
190. Kuo TT, Chen SY, Chan HL: Tinea infection histologically simulating eosinophilic pustular folliculitis. *J Cutan Pathol* **13**(2):118-122, 1986
191. Haupt HM, Stern JB, Weber CB: Eosinophilic pustular folliculitis: Fungal folliculitis? *J Am Acad Dermatol* **23**(5 Pt 2):1012-1014, 1990
192. Shindo M et al: Trichophyton rubrum infection histologically identical to eosinophilic pustular folliculitis. *Clin Exp Dermatol* **33**(4):500-501, 2008
193. Maejima H, Mukai H, Hikaru E: Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. *Acta Derm Venereol* **82**(4):316-317, 2002
194. Mizoguchi S et al: Eosinophilic pustular folliculitis induced by carbamazepine. *J Am Acad Dermatol* **38**(4):641-643, 1998
195. Kishimoto S et al: Eosinophilic pustular folliculitis in association with nevoid basal cell carcinoma syndrome. *Acta Derm Venereol* **81**(3):202-204, 2001
196. Kus S et al: Eosinophilic pustular folliculitis (Ofuji's disease) exacerbated with pregnancies. *J Eur Acad Dermatol Venereol* **20**(10):1347-1348, 2006
197. Kimura K et al: A case of eosinophilic pustular folliculitis (Ofuji's disease) induced by patch and challenge tests with indeloxazine hydrochloride. *J Dermatol* **23**(7):479-483, 1996

198. Takematsu H, Tagami H: Eosinophilic pustular folliculitis. Studies on possible chemotactic factors involved in the formation of pustules. *Br J Dermatol* **114**(2):209-215, 1986
199. Selvaag E et al: Eosinophil cationic protein in eosinophilic pustular folliculitis: An immunohistochemical investigation. *Clin Exp Dermatol* **22**(5):255-256, 1997
200. Fushimi M et al: Eosinophilic pustular folliculitis effectively treated with recombinant interferon-gamma: Suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells. *Br J Dermatol* **134**(4):766-772, 1996
201. Otsuka A et al: Treatment of eosinophilic pustular folliculitis with ciclosporin: Suppression of mRNA expression of IL-4 and IL-13. *J Eur Acad Dermatol Venereol* **24**(12):1489-1491, 2010
202. Asgari M et al: Neonatal eosinophilic pustulosis. *Int J Dermatol* **45**(2):131-134, 2006
203. McCalmont TH et al: Eosinophilic folliculitis. The histologic spectrum. *Am J Dermatopathol* **17**(5):439-446, 1995
204. Buezo GF et al: HIV-Associated eosinophilic folliculitis and follicular mucinosis. *Dermatology* **197**(2):178-180, 1998
205. Lee MW et al: Failure to detect clonality in eosinophilic pustular folliculitis with follicular mucinosis. *Acta Derm Venereol* **84**(4):305-307, 2004
206. Kabashima K, Sakurai T, Miyachi Y: Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. *Br J Dermatol* **151**(4):949-950, 2004
207. Ellis E, Scheinfeld N: Eosinophilic pustular folliculitis: A comprehensive review of treatment options. *Am J Clin Dermatol* **5**(3):189-197, 2004
208. Fukamachi S et al: Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. *Acta Derm Venereol* **89**(2):155-159, 2009
209. Ota T et al: Eosinophilic pustular folliculitis (Ofuji's disease): Indomethacin as a first choice of treatment. *Clin Exp Dermatol* **26**(2):179-181, 2001
210. Satoh T et al: Indomethacin-induced reduction in CRTH2 in eosinophilic pustular folliculitis (Ofuji's disease): A proposed mechanism of action. *Acta Derm Venereol* **90**(1):18-22, 2010
211. Burgess GH, Mehregan AH, Drinnan AJ: Eosinophilic ulcer of the tongue. *Arch Dermatol* **113**(5):644-645, 1977
212. Mezei MM et al: Eosinophilic ulcer of the oral mucosa. *J Am Acad Dermatol* **33**(5 Pt 1):734-740, 1995
213. el-Mofty SK et al: Eosinophilic ulcer of the oral mucosa. Report of 38 new cases with immunohistochemical observations. *Oral Surg Oral Med Oral Pathol* **75**(6):716-722, 1993
214. Segura S, Pujol RM: Eosinophilic ulcer of the oral mucosa: A distinct entity or a non-specific reactive pattern? *Oral Dis* **14**(4):287-295, 2008
215. Segura S et al: Eosinophilic ulcer of the oral mucosa: Another histological simulator of CD30+lymphoproliferative disorders. *Br J Dermatol* **155**(2):460-463, 2006
216. Cheng JF et al: Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. *J Allergy Clin Immunol* **99**(5):683-692, 1997
217. Davis MD et al: Interactions of eosinophil granule proteins with skin: Limits of detection, persistence, and vasopermeabilization. *J Allergy Clin Immunol* **112**(5):988-994, 2003
218. Peters MS et al: Localization of eosinophil granule major basic protein in chronic urticaria. *J Invest Dermatol* **81**(1):39-43, 1983
219. Peters MS et al: Extracellular deposition of eosinophil granule major basic protein in pressure urticaria. *J Am Acad Dermatol* **16**(3 Pt 1):513-517, 1987
220. Leiferman KM et al: Evidence for eosinophil degranulation with deposition of granule major basic protein in solar urticaria. *J Am Acad Dermatol* **21**(1):75-80, 1989
221. McEvoy MT et al: Immunohistological comparison of granulated cell proteins in induced immediate urticarial dermatographism and delayed pressure urticaria lesions. *Br J Dermatol* **133**(6):853-860, 1995
222. Katzen DR et al: Hypereosinophilia and recurrent angioneurotic edema in a 2 1/2-year-old girl. *Am J Dis Child* **140**(1):62-64, 1986
223. Songsiridej V et al: Facial edema and eosinophilia. Evidence for eosinophil degranulation. *Ann Intern Med* **103**(4):503-506, 1985
224. Wolf C et al: Episodic angioedema with eosinophilia. *J Am Acad Dermatol* **20**(1):21-27, 1989
225. Putterman C et al: Episodic angioedema with eosinophilia: A case associated with T cell activation and cytokine production. *Ann Allergy* **70**(3):243-248, 1993
226. Butterfield JH et al: Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. *Blood* **79**(3):688-692, 1992

227. Morgan SJ et al: Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome). *Leuk Lymphoma* **44**(9):1623-1625, 2003
228. van Haelst Pisani C et al: Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. *Blood* **78**(6):1538-1544, 1991
229. Mehregan DR et al: Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. *Arch Dermatol* **128**(8):1055-1059, 1992
230. Kephart GM et al: Deposition of eosinophil granule major basic protein onto microfilariae of *Onchocerca volvulus* in the skin of patients treated with diethylcarbamazine. *Lab Invest* **50**(1):51-61, 1984
231. Leiferman KM et al: Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. *N Engl J Med* **313**(5):282-285, 1985
232. Ackerman SJ et al: Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis. *J Immunol* **144**(10):3961-3969, 1990
233. Leiferman KM et al: Eosinophils. In: *Atopic Dermatitis*, 2nd edition, edited by T Bieber, DYM Leung. New York, Informa Healthcare USA, 2009, Chapter 10, pp. 195-228
234. Cheung PF et al: Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: Implication for the immunopathogenesis of atopic dermatitis. *Int Immunol* **22**(6):453-467, 2010
235. Perez GL et al: Mast cells, neutrophils, and eosinophils in prurigo nodularis. *Arch Dermatol* **129**(7):861-865, 1993
236. Jacyk WK et al: Pachydermatous eosinophilic dermatitis. *Br J Dermatol* **134**(3):469-474, 1996
237. Johansson O et al: Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. *Arch Dermatol Res* **292**(8):371-378, 2000
238. Suto H et al: NC/Nga mice: A mouse model for atopic dermatitis. *Int Arch Allergy Immunol* **120**(Suppl. 1):70-75, 1999
239. Tsukuba T et al: Association of cathepsin E deficiency with development of atopic dermatitis. *J Biochem (Tokyo)* **134**(6):893-902, 2003
240. Yagi R et al: Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. *J Immunol* **168**(4):2020-2027, 2002
241. Chan LS, Robinson N, Xu L: Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis. *J Invest Dermatol* **117**(4):977-983, 2001
242. Fang D et al: Dysregulation of T lymphocyte function in itchy mice: A role for Itch in TH2 differentiation. *Nat Immunol* **3**(3):281-287, 2002
243. Bahrami S et al: Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. *Arch Dermatol* **142**(2):155-161, 2006
244. Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). *Semin Cutan Med Surg* **15**(4):250-257, 1996
245. Lens S et al: Severe acute hepatitis in the dress syndrome: Report of two cases. *Ann Hepatol* **9**(2):198-201, 2010
246. Ramdial PK, Naidoo DK: Drug-induced cutaneous pathology. *J Clin Pathol* **62**(6):493-504, 2009
247. Borrego L et al: Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. *Am J Pathol* **148**(3):897-909, 1996
248. Stahle-Backdahl M et al: 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. *J Clin Invest* **93**(5):2022-2030, 1994
249. Shrikhande M, Hunziker T, Braathen LR, Pichler WJ, Dahinden CA, Yawalkar N: Increased co-expression of eotaxin and interleukin 5 in bullous pemphigoid. *Acta Derm Venereol* **80**:277-280, 2000
250. Scheman AJ et al: Evidence for eosinophil degranulation in the pathogenesis of herpes gestationis. *Arch Dermatol* **125**(8):1079-1083, 1989
251. Borrego L et al: Polymorphic eruption of pregnancy and herpes gestationis: Comparison of granulated cell proteins in tissue and serum. *Clin Exp Dermatol* **24**(3):213-225, 1999
252. Ambros-Rudolph CM et al: The specific dermatoses of pregnancy revisited and reclassified: Results of a retrospective two-center study on 505 pregnant patients. *J Am Acad Dermatol* **54**(3):395-404, 2006
253. Roger D et al: Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. *Arch Dermatol* **130**(6):734-739, 1994

254. Noguchi H et al: Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. *Am J Pathol* **140**(2):521-528, 1992
255. Pegorier S et al: Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. *J Immunol* **177**(7):4861-4869, 2006
256. Antic M, Lautenschlager S, Itin PH: Eosinophilic fasciitis 30 years after – What do we really know? Report of 11 patients and review of the literature. *Dermatology* **213**(2):93-101, 2006
257. Hertzman PA et al: Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. *N Engl J Med* **322**(13):869-873, 1990
258. Mori Y, Kahari VM, Varga J: Scleroderma-like cutaneous syndromes. *Curr Rheumatol Rep* **4**(2):113-122, 2002
259. Varga J et al: Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. *J Rheumatol* **18**(2):259-263, 1991
260. Varga J, Kahari VM: Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. *Curr Opin Rheumatol* **9**(6):562-570, 1997
261. Uitto J et al: Eosinophilia-myalgia syndrome. *Int J Dermatol* **31**(4):223-228, 1992
262. Martin RW et al: The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. *Ann Intern Med* **113**(2):124-134, 1990
263. Diggle GE: The toxic oil syndrome: 20 years on. *Int J Clin Pract* **55**(6):371-375, 2001
264. Ten RM et al: Participation of eosinophils in the toxic oil syndrome. *Clin Exp Immunol* **82**(2):313-317, 1990
265. Martinez-Cabot A, Messeguer A: Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: A potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. *Chem Res Toxicol* **20**(10):1556-1562, 2007
266. Rieber N, Belohradsky BH: AHR activation by tryptophan—Pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome? *Immunol Lett* **128**(2):154-155, 2010
267. Churg J, Strauss L: Allergic granulomatosis, allergic angitis, and periarteritis nodosa. *Am J Pathol* **27**(2):277-301, 1951
268. Davis MD et al: Cutaneous manifestations of Churg-Strauss syndrome: A clinicopathologic correlation. *J Am Acad Dermatol* **37**(2 Pt 1):199-203, 1997
269. Drage LA et al: Evidence for pathogenic involvement of eosinophils and neutrophils in Churg-Strauss syndrome. *J Am Acad Dermatol* **47**(2):209-216, 2002
270. Ishibashi M et al: Churg-Strauss syndrome with coexistence of eosinophilic vasculitis, granulomatous phlebitis and granulomatous dermatitis in bullous pemphigoid-like blisters. *J Cutan Pathol* **38**(3):290-294, 2011
271. Chen KR et al: Recurrent cutaneous necrotizing eosinophilic vasculitis. A novel eosinophil-mediated syndrome. *Arch Dermatol* **130**(9):1159-1166, 1994
272. Carlson JA, Chen KR: Cutaneous vasculitis update: Neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. *Am J Dermatopathol* **29**(1):32-43, 2007
273. Chen KR et al: Eosinophilic vasculitis in connective tissue disease. *J Am Acad Dermatol* **35**(2 Pt 1):173-182, 1996
274. Cormier SA et al: Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. *J Leukoc Biol* **79**(6):1131-1139, 2006
275. van Doorn R, Scheffer E, Willemze R: Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: A clinicopathologic and follow-up study of 51 patients. *Arch Dermatol* **138**(2):191-198, 2002
276. Shapiro PE, Pinto FJ: The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. *Am J Surg Pathol* **18**(7):645-667, 1994
277. Kong YY et al: Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: A clinicopathological, immunophenotypic and molecular study of nine cases. *Histopathology* **55**(2):189-196, 2009
278. Davis MD et al: Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: A clinical, histopathologic, and immunopathologic study of eight patients. *J Am Acad Dermatol* **39**(1):27-35, 1998
279. Rueda RA et al: Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy. *Arch Dermatol* **135**:804-810, 1999

- 280.** Delaibatiki M, Hardie C, Temple-Camp C: Eosinophilic, polymorphic, and pruritic eruption associated with radiotherapy after chest wall irradiation. *NZMJ* **122**:99-101, 2009